Related Experiment Video
Updated: Nov 21, 2025

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
COVID-19 and acute kidney injury
Lale A Ertuğlu1, Asiye Kanbay2, Barış Afşar3
1Department of Internal Medicine, Koc University School of Medicine, Istanbul, Turkey.
Insights
COVID-19 significantly impacts kidneys, causing acute kidney injury (AKI) in severe cases. Understanding AKI mechanisms and implementing protective measures is crucial for patient outcomes.
Area of Science:
- Nephrology
- Infectious Diseases
- Virology
Background:
- The COVID-19 pandemic, caused by SARS-CoV-2, has led to widespread health issues globally.
- Kidney damage, including proteinuria, hematuria, and AKI, is frequently observed in hospitalized COVID-19 patients.
- Acute kidney injury (AKI) is particularly common in severe and critical COVID-19 cases and is linked to increased mortality.
Purpose of the Study:
- To review the prevalence and outcomes of AKI in COVID-19 patients.
- To explore the potential mechanisms underlying COVID-19-associated kidney damage.
- To suggest strategies for preventing kidney injury in COVID-19.
Main Methods:
- Review of current literature on COVID-19 and kidney injury.
- Analysis of histopathological findings in kidney tissues from COVID-19 patients.
- Discussion of potential therapeutic targets and organ-protective measures.
Main Results:
- COVID-19 frequently causes kidney damage, with AKI being a significant predictor of mortality.
- Pathological findings suggest direct SARS-CoV-2 infection of renal cells and acute tubular necrosis.
- Other contributing factors may include rhabdomyolysis and glomerulopathies.
Conclusions:
- AKI is a serious complication of COVID-19 with unclear pathophysiology.
- Further research into antiviral and anti-inflammatory treatments is ongoing.
- Organ-protective strategies are essential for managing kidney health during the pandemic.
Abstract:
The Coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) started in December 2019 and has affected millions of lives worldwide, while many aspects of the illness are still unknown. Current data show that many hospitalized COVID-19 patients suffer from kidney damage, in the form of proteinuria, hematuria or acute kidney injury (AKI). AKI is especially prevalent among severe and critically ill COVID-19 patients and is a predictor of mortality. The pathophysiology of AKI in COVID-19 is unclear. Early reports of histopathologic examination from autopsied kidney tissue show SARS-CoV-2 viral particles in renal tubular cells and podocytes, suggesting direct viral infection, as well as findings of acute tubular necrosis, while rhabdomyolysis-associated AKI and glomerulopathies may also occur. As of today, only remdesivir has been authorized to treat COVID-19. Ongoing research investigates potential of anti-viral and anti-inflammatory agents along with safety and efficacy of commonly prescribed drugs such as renin-angiotensin-aldosterone system blockers. This review discusses the prevalence of AKI and its association with outcome, while highlighting possible mechanisms of AKI and suggesting organ protective measures to prevent the development of kidney damage.
Related Concept Videos
Acute Kidney Injury I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury VI: Nursing Management

